Vanda Pharmaceuticals acquires U.S. and Canadian rights to Ponvory (ponesimod), a selective S1P1R modulator, approved for patients with relapsing multiple sclerosis
Vanda Pharmaceuticals Inc. announced that it has acquired U.S. and Canadian rights to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company. Ponvory is approved… read more.
